Loading...
•
Mar 31, 2025
Intellia Q1 2025 Earnings Report
Intellia Therapeutics reported its first quarter 2025 financial results and highlighted recent company progress.
Key Takeaways
Intellia Therapeutics reported a net loss of $114.3 million for the first quarter of 2025, compared to a net loss of $107.4 million in the same period last year. Collaboration revenue decreased to $16.6 million from $28.9 million, primarily due to a decrease in the AvenCell license and collaboration agreement. The company ended the quarter with $707.1 million in cash, cash equivalents, and marketable securities, and expects to fund operations into the first half of 2027.
Intellia is on track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025.
The first patient was dosed in the global Phase 3 MAGNITUDE-2 study for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).
Enrollment in the global Phase 3 MAGNITUDE trial for ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projections.
The company expects to present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study of nex-z in the second half of 2025.
Revenue by Segment
Forward Guidance
Intellia Therapeutics anticipates several key milestones and data readouts in the coming quarters, including the completion of enrollment for a pivotal Phase 3 study and the submission of a Biologics License Application.
Positive Outlook
- On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025.
- Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projections, anticipating over 550 total patients by year-end.
- Expect to present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study of nex-z in the second half of 2025, including updated measures of clinical efficacy and safety.
- The company is on track to submit a Biologics License Application (BLA) in the second half of 2026.
- Cash, cash equivalents and marketable securities are expected to fund operations into the first half of 2027.
Challenges Ahead
- The decrease in collaboration revenue was mainly driven by a decrease in collaboration revenue under the AvenCell license and collaboration agreement.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...